Mandate

Vinge advises Cell Impact in connection with its fully guaranteed rights issue of SEK 349 million

December 01, 2021 Capital Markets and Public M&A

Vinge advises Cell Impact AB (publ) in connection with a fully guaranteed rights issue which will provide Cell Impact with gross issue proceeds of SEK 349 million

Cell Impact is a global supplier of advanced flow plates to fuel cell manufacturers. The company has developed and patented a unique scalable method for high-velocity forming, Cell Impact Forming™, which makes it possible to produce flow plates with more advanced designs, which in turn creates more cost and energy-efficient fuel cells compared to conventional forming methods.

Vinge’s team consisted of Johan Larsson, Dain Hård Nevonen, Anna Jonsson, Rikard Lindahl, Joel Magnusson and Lorin Arabi.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025